SCHEMBL5539808

SCHEMBL5539808

CC(C)Oc1ccc(O[CH]c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 1/20 0.50
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 3/20 0.41
GAA P10253 3/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 2/20 0.41
MEN1 O00255 1/20 0.41
PARP10 Q53GL7 1/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
CNR2 P34972 1/20 0.39
TRPA1 O75762 1/20 0.38
SIRT1 Q96EB6 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
CYP1A2 P05177 1/20 0.37
PKM P14618 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544917 0.81 TYR (0.41) KMT2ALMNATP53MEN1NPC1
SCHEMBL25836762 0.80 TRPA1 (0.61) ALDH1A3KMT2ALMNATP53NPC1
SCHEMBL536918 0.79 TSHR (0.43) ALDH1A1LMNATRPA1
SCHEMBL5545232 0.78 PPARG (0.47) KMT2ALMNAMEN1NPC1RAB9A
SCHEMBL5546634 0.78 TRPA1 (0.63) KMT2AALDH1A1LMNATP53MEN1
SCHEMBL5542469 0.77 ALDH1A1 (0.42) KMT2AALDH1A1GAALMNAMEN1
SCHEMBL12394 0.76 KMT2A (0.54) ALDH1A3KMT2AALDH1A1GAALMNA
Ammonia Solution, Strong SCHEMBL8909178 0.74 KMT2A (0.52) ALDH1A3KMT2AALDH1A1GAALMNA
Hydrogen Sulfide SCHEMBL27992657 0.74 KMT2A (0.52) ALDH1A3KMT2AALDH1A1GAALMNA
Phosphine SCHEMBL28772208 0.74 KMT2A (0.52) ALDH1A3KMT2AALDH1A1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A3 177/4885KMT2A 4267/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.